Bekelis Kimon, Gottlieb Dan, Su Yin, Labropoulos Nicos, Bovis George, Lawton Michael T, MacKenzie Todd A
Section of Neurosurgery, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, New Hampshire, USA.
J Neurointerv Surg. 2017 Mar;9(3):324-328. doi: 10.1136/neurintsurg-2016-012313. Epub 2016 Mar 24.
The cost difference between the two treatment options (surgical clipping and endovascular therapy) for unruptured cerebral aneurysms remains an issue of debate. We investigated the association between treatment method for unruptured cerebral aneurysms and Medicare expenditures in elderly patients.
We performed a cohort study of 100% Medicare fee-for-service claims data for elderly patients who underwent treatment for unruptured cerebral aneurysms from 2007 to 2012. In order to control for measured confounding we used multivariable regression analysis with mixed effects to account for clustering at the Hospital Referral Region (HRR) level. An instrumental variable (regional rates of endovascular treatment) analysis was used to control for unmeasured confounding by creating pseudo-randomization on the treatment method.
During the study period 8705 patients underwent treatment for unruptured cerebral aneurysms and met the inclusion criteria. Of these, 2585 (29.7%) had surgical clipping and 6120 (70.3%) had endovascular treatment. The median total Medicare expenditures in the first year after the admission for the procedure were $46 800 (IQR $31 000-$74 400) for surgical clipping and $48 100 (IQR $34 500-$73 900) for endovascular therapy. When we adjusted for unmeasured confounders, using an instrumental variable analysis, clipping was associated with increased 7-day Medicare expenditures by $3527 (95% CI $972 to $5736) and increased 1-year Medicare expenditures by $15 984 (95% CI $9017 to $22 951).
In a cohort of Medicare patients, after controlling for unmeasured confounding, we demonstrated that surgical clipping of unruptured cerebral aneurysms was associated with increased 1-year expenditures compared with endovascular treatment.
未破裂脑动脉瘤的两种治疗方案(手术夹闭和血管内治疗)之间的成本差异仍是一个有争议的问题。我们调查了未破裂脑动脉瘤的治疗方法与老年患者医疗保险支出之间的关联。
我们对2007年至2012年接受未破裂脑动脉瘤治疗的老年患者的100%医疗保险按服务收费索赔数据进行了队列研究。为了控制已测量的混杂因素,我们使用了多变量回归分析和混合效应模型,以考虑医院转诊区域(HRR)层面的聚类情况。采用工具变量(血管内治疗的区域率)分析,通过对治疗方法进行伪随机化来控制未测量的混杂因素。
在研究期间,8705例患者接受了未破裂脑动脉瘤的治疗并符合纳入标准。其中,2585例(29.7%)接受了手术夹闭,6120例(70.3%)接受了血管内治疗。手术夹闭术后第一年医疗保险总支出中位数为46,800美元(四分位间距31,000 - 74,400美元),血管内治疗为48,100美元(四分位间距34,500 - 73,900美元)。当我们使用工具变量分析调整未测量的混杂因素后,夹闭术与7天医疗保险支出增加3527美元(95%置信区间972美元至5736美元)以及1年医疗保险支出增加15,984美元(95%置信区间9017美元至22,951美元)相关。
在一组医疗保险患者中,在控制未测量的混杂因素后,我们证明与血管内治疗相比,未破裂脑动脉瘤的手术夹闭术与1年支出增加相关。